GET DAILY SIGNALSGossamer Bio (GOSS) Ahead of Q3 2026 Earnings: What Matters Most
Key Takeaways
- Gossamer Bio is set to report third-quarter 2026 results in early November 2026, with analysts expecting another net loss.
- Attention centers on updates regarding the regulatory path for seralutinib, the lead candidate targeting pulmonary arterial hypertension (PAH).
- The cash position extending into the first quarter of 2027 and the proposed convertible debt restructuring stand out as key areas of focus.
- A 1-for-80 reverse stock split completed in September 2026 adds complexity to year-over-year per-share comparisons.
- Recent quarters show revenue often beating consensus thanks to collaboration-related payments, while EPS results have been mixed.
Why This Earnings Report Stands Out
Gossamer Bio develops seralutinib, an inhaled treatment for PAH. This quarter’s update comes at a notable time following the reacquisition of worldwide rights to the candidate, a workforce reduction of roughly half the employees, and efforts to restructure convertible debt. With Phase 3 PROSERA data already available and an NDA submission planned for September 2026, the report should provide clarity on cash levels, spending patterns, and progress toward potential approval. I checked comparable names using Tickeron’s AI Screener to see how GOSS fits within the broader biotech landscape.
Earnings Estimates and Recent Trends
Consensus points to ongoing net losses for the third quarter, with revenue near $5 million. The September 2026 reverse split means per-share figures require careful comparison across sources. Pre-split loss estimates range from about $0.05 to $0.14 per share.
In the second quarter, revenue reached $9.24 million against a $3.6 million consensus, while the $0.08 per-share loss beat the $0.12 estimate. The first quarter showed $16.95 million in revenue versus roughly $4.7 million expected, though the $0.20 loss missed the $0.17 consensus. Beyond the headline numbers, focus will likely fall on cash balances, R&D and G&A expenses, and any fresh details on the NDA timeline targeted for September 2026 with possible approval in the third quarter of 2027.
Market Sentiment Heading Into the Report
Investor caution appears elevated given the stock’s volatility, which reflects both clinical advances and ongoing financial questions. After first-quarter results, shares dropped sharply in after-hours trading before a partial recovery. The reverse split aimed to support the price and maintain exchange listing, yet it also underscores the pressures faced. Investors continue to balance the possibility of a meaningful approval for seralutinib against the chance that additional capital may be needed before that milestone.
Key Factors to Watch Going Forward
The regulatory timeline for seralutinib remains the primary near-term driver. Management has outlined plans to submit an NDA based on Phase 3 PROSERA results plus Phase 2 TORREY data, with a September 2026 target. Confirmation of the submission and subsequent FDA acceptance will be closely monitored.
Cash runway is equally important. As of March 31, 2026, the company held approximately $99 million in cash and marketable securities, sufficient to fund operations only into the first quarter of 2027. The proposed note exchange, intended to lower debt and extend maturity, hinges on strong noteholder participation. Operating expenses after the workforce reduction and any updates on the paused PH-ILD program also warrant attention, as these elements will determine whether the company can reach potential approval and commercialization without further financing needs.
Integrating AI Tools Into Biotech Analysis
When reviewing clinical-stage names like GOSS, I often turn to Tickeron’s AI Screener to quickly filter peers by fundamentals, volatility, and technical signals. It helps surface comparable companies and spot patterns that might otherwise require hours of manual work. This kind of structured scan keeps my focus on the data that actually moves the needle for names in this space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GOSS saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for GOSS moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 48 similar instances where the indicator exited the overbought zone. In 45 of the 48 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GOSS as a result. In 72 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GOSS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
GOSS broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GOSS entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GOSS just turned positive on October 12, 2026. Looking at past instances where GOSS's MACD turned positive, the stock continued to rise in 36 of 38 cases over the following month. The odds of a continued upward trend are 90%.
Following a +16.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where GOSS advanced for three days, in 215 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.647) is normal, around the industry mean (3.051). P/E Ratio (-0.235) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.666) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. GOSS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GOSS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology
Industry Biotechnology
Advertisement